Health Care • Medical/Dental Instruments
$0.99 ▲ +0.10
(+11.40%)
MKT CAP: $13.2M • VOL: 710.9K
52W L $1 52W H $29
ROARABLE / RQD
D+ • 52/100
PIOTROSKI
2 / 9
GUTS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $93.0K | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | $43.0K | — |
| Gross Margin % | — | 46.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$96.8M | -$93.5M | -$50.8M |
| Operating Margin % | — | -80.0% | — |
| Net Income (GAAP) | -$141.0M | -$68.7M | -$77.1M |
| EBITDA (Normalized) | -$96.4M | -$92.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$90.3M | -$65.5M | -$42.8M |
| Capital Expenditures (CapEx) | $557.0K | $1.8M | — |
| Free Cash Flow (FCF) | -$90.9M | -$67.3M | -$42.8M |
| FCF Margin % | — | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $81.5M | $67.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $9.5M | $28.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GUTS.